EverydayHealthLogo
Dr. Ronald Levy, MD

Dr. Ronald Levy, MD

Stanford, CA

Accepting patients

Affiliated with a Castle Connolly Top Hospital

    Who is Dr. Levy, Medical Oncologist in Stanford, CA?

    Dr. Ronald Levy, MD is a Medical Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. He is board certified by the American Board of Internal Medicine. Dr. Levy graduated from Stanford University School of Medicine and completed his residency at Massachusetts General Hospital. Dr. Levy is fluent in English and Spanish, and is currently seeing new patients. Dr. Levy’s practice accepts Medicaid, Medicare, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Levy’s office at (650) 723-4000.

    Where did Dr. Levy go to medical school and complete their residency?

    • Fellowship: Stanford University School of Medicine,Stanford, Ca, United States

    • Residency: Massachusetts General Hospital | Massachusetts General Hospital Program

    • Medical School: Stanford University School of Medicine

    Is Dr. Levy board certified in Medical Oncologist?

    Yes, Dr. Ronald Levy, MD is board certified by the American Board of Internal Medicine since 1979, American Board of Internal Medicine since 1973

    What languages does Dr. Levy speak?

    Dr. Levy and their clinical team can communicate with patients in the following languages:

    • English

    • Spanish

    What conditions does Dr. Levy treat?

    As a Medical Oncologist, Dr. Levy diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Levy. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.

    Also known as:

    • Non-Hodgkin Lymphoma
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
    • Diffuse Large B-cell Lymphoma
    • Lymphoma
    • Lymphatic Cancer
    • Lymphosarcoma
    • NHL
    • Follicular Non-Hodgkin Lymphoma
    • FL
    • Nodular Lymphoma
    • Follicular Lymphatic Cancer
    • Indolent Lymphoma
    • Follicular Lymphoma Cancer
    • MCL
    • Mantle Cell Lymphoma Cancer
    • DLBCL
    • Aggressive B-cell Lymphoma
    • Diffuse B-cell Lymphoma

    ICD-10 Codes:

    • C8580: Other specified types of non-Hodgkin lymphoma, unspecified site
    • C8290: Follicular lymphoma, unspecified, unspecified site
    • C8218: Follicular lymphoma grade II, lymph nodes of multiple sites
    • C8298: Follicular lymphoma, unspecified, lymph nodes of multiple sites
    • C8310: Mantle cell lymphoma, unspecified site
    • C8338: Diffuse large B-cell lymphoma, lymph nodes of multiple sites
    • C8211: Follicular lymphoma grade II, lymph nodes of head, face, and neck

    Which procedures does Dr. Levy perform as a Medical Oncologist?

    As a Medical Oncologist, procedures performed by a Dr. Ronald Levy may include:

    For detailed information, please contact Dr. Levy's office.

    Does Dr. Levy accept my insurance?

    Dr. Levy accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.

    What insurance plans does Dr. Levy accept in Stanford, CA?

    Dr. Levy in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.

    Top Insurances

    • Medicaid

    • Medicare

    • UnitedHealthcare

    View All Insurances

    Where is Dr. Levy's office located?

    Dr. Ronald Levy's Primary Practice

    300 Pasteur Dr

    Stanford, CA 94305

    (650) 723-4000

    Get Directions

    Dr. Ronald Levy's Practice 2

    875 Blake Wilbur Dr

    Palo Alto, CA 94304

    Get Directions

    Recognitions

    Publications

    High PD-1 expression

    Blood, 2013

    A vaccine directed to B cells

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2012

    CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T

    AMERICAN JOURL OF PATHOLOGY, 2012

    Combition strategies to enhance antitumor ADCC

    IMMUNOTHERAPY, 2012

    Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2012

    Prolonged disease-free survival

    AMERICAN JOURL OF HEMATOLOGY, 2011

    Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results

    JOURL OF CLINICAL ONCOLOGY, 2011

    The Efficacy of HGAL and LMO2 in the Separation of Lymphom

    AMERICAN JOURL OF CLINICAL PATHOLOGY, 2011

    Immunomodulating antibodies and drugs for the treatment of hematological maligncies

    CANCER AND METASTASIS REVIEWS, 2011

    In Situ Vaccition With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

    JOURL OF CLINICAL ONCOLOGY, 2010

    Immunoarchitectural Patterns in Follicular Lymphoma

    AMERICAN JOURL OF SURGICAL PATHOLOGY, 2010

    B-cell sigling networks reveal a negative prognostic human lymphoma cell subset that emerges during

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2010

    C-C Chemokine Receptor 1 Expression in Human Hematolymphoid Neoplasia

    AMERICAN JOURL OF CLINICAL PATHOLOGY, 2010

    CD81 protein is expressed at high levels in normal germil center B cells

    HUMAN PATHOLOGY, 2010

    Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma

    NEW ENGLAND JOURL OF MEDICINE, 2009

    Anti-idiotype antibody response after vaccition correlates with better overall survival in

    BLOOD, 2009

    The Transcription Factor LMO2 Is a Robust Marker of Vascular Endothelium and Vascular Neoplasms

    AMERICAN JOURL OF CLINICAL PATHOLOGY, 2009

    Idiotype vaccition for lymphoma: moving towards optimisation

    LEUKEMIA & LYMPHOMA, 2009

    Follicular lymphoma B cells induce the conversion of conventiol CD4

    INTERTIOL JOURL OF CANCER, 2009

    Tumor-specific recombint idiotype immunisation after chemotherapy as initial treatment for

    LEUKEMIA & LYMPHOMA, 2009

    Neither CD68+Nor CD163+Macrophages Are Associated with Decreased Survival in Follicular Lymphoma

    Gratzinger, D., Ai, W., Tibshirani, R., Levy, R., tkum, Y., 2008

    LMO2 protein expression predicts survival in patients with diffuse large B

    JOURL OF CLINICAL ONCOLOGY, 2008

    Minor BCL2 breakpoints in follicular lymphoma

    JOURL OF MOLECULAR DIAGNOSTICS, 2007

    Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the

    JOURL OF IMMUNOLOGY, 2007

    Therapeutic vaccition against murine lymphoma by intratumoral injection of recombint fowlpox virus

    CANCER RESEARCH, 2007

    Cell-free production of scFv fusion proteins

    BLOOD, 2007

    The oncoprotein LMO2 is expressed in normal germil-center B cells and in human B-cell lymphomas

    BLOOD, 2007

    Expression of the R-binding protein VICKZ in normal hematopoietic tissues and neoplasms

    HAEMATOLOGICA-THE HEMATOLOGY JOURL, 2007

    Expression of the human germil center-associated lymphoma

    BLOOD, 2007

    Altered B-cell receptor sigling kinetics distinguish human follicular lymphoma. B cells from tumor

    BLOOD, 2006

    Kinetics of B cell receptor sigling

    JOURL OF IMMUNOLOGY, 2006

    Production of myeloid dendritic cells

    CYTOTHERAPY, 2006

    Therapeutic vaccition against murine lymphoma by intratumoral injection of ive dendritic cells

    CANCER RESEARCH, 2005

    Expression of the human germil center-associated lymphoma (HGAL) protein

    BLOOD, 2005

    Clinical outcome of lymphoma patients after idiotype vaccition is correlated with humoral immune

    JOURL OF CLINICAL ONCOLOGY, 2004

    AID is expressed in germil center B-cell-like

    LEUKEMIA, 2004

    Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

    NEW ENGLAND JOURL OF MEDICINE, 2004

    Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas

    BRITISH JOURL OF HAEMATOLOGY, 2004

    TCR vaccines against a murine T cell lymphoma

    JOURL OF IMMUNOLOGY, 2004

    Two immunoglobulin G fragment C receptor polymorphisms independently predict response

    JOURL OF CLINICAL ONCOLOGY, 2003

    Alysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma

    LEUKEMIA & LYMPHOMA, 2003

    Higher grade transformation of follicular lymphoma

    SEMIRS IN CANCER BIOLOGY, 2003

    Diffuse large B-cell lymphoma: Insights gained from gene expression profiling

    INTERTIOL JOURL OF HEMATOLOGY, 2003

    Antitumor immunity after vaccition with B lymphoma cells overexpressing a triad of costimulatory

    JOURL OF THE TIOL CANCER INSTITUTE, 2003

    Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid maligncies

    LEUKEMIA, 2003

    Variation in gene expression patterns in follicular lymphoma and the response to rituximab

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2003

    Immunogenicity of a plasmid D vaccine encoding chimeric idiotype in patients with B-cell lymphoma

    CANCER RESEARCH, 2002

    BCL-6 mR expression in higher grade transformation of follicle center lymphoma

    LEUKEMIA, 2002

    Transformation of follicular lymphoma to diffuse large-cell lymphoma

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2002

    Idiotype-pulsed dendritic cell vaccition for B-cell lymphoma

    BLOOD, 2002

    Re: Akasaka, H., et al., Molecular atomy of BCL6 translocations revealed by long

    Cancer research, 2001

    Idiotype-encoding recombint adenoviruses provide protective immunity against murine B

    BLOOD, 2001

    T cell antigen receptor vaccines for active therapy of T cell maligncies

    Reddy, S. A., Okada, C., Wong, C., Bahler, D., Levy, R., 2001

    Idiotype vaccition following ABMT can stimulate specific anti

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001

    The inference of antigen selection on Ig genes

    JOURL OF IMMUNOLOGY, 2000

    A perspective on monoclol antibody therapy: Where we have been and where we are going

    Levy, R., 2000

    Rituximab anti-CD20 monoclol antibody therapy in non-Hodgkin's lymphoma

    JOURL OF CLINICAL ONCOLOGY, 2000

    Ongoing immunoglobulin somatic mutation in germil center B cell-like but not in activated B cell

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2000

    Combition immunotherapy of relapsed or refractory low-grade or follicular non

    CLINICAL CANCER RESEARCH, 2000

    Recombint adenovirus vaccine encoding a chimeric T

    CANCER RESEARCH, 2000

    Linkage of foreign carrier protein to a self

    JOURL OF IMMUNOLOGY, 2000

    Molecular alysis of immunoglobulin genes in diffuse large B-cell lymphomas

    BLOOD, 2000

    Mutation alysis of the 5 ' noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma

    BLOOD, 2000

    Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

    TURE, 2000

    Idiotype vaccition using dendritic cells after autologous peripheral blood progenitor cell

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000

    Cytokine fusion constructs as D vaccines against tumors.

    Methods in molecular medicine, 2000

    Karnofsky Lecture: Immunotherapy of lymphoma

    JOURL OF CLINICAL ONCOLOGY, 1999

    1999 keystone symposium on B lymphocyte biology and disease: B cell maligncy II session.

    Levy, R.

    Single-agent monoclol antibody efficacy in bulky non-Hodgkin's lymphoma

    JOURL OF CLINICAL ONCOLOGY, 1999

    D vaccition against the idiotype of a murine B cell lymphoma: Mechanism of tumor protection

    JOURL OF IMMUNOLOGY, 1999

    Idiotype vaccition using dendritic cells after autologous peripheral blood stem cell

    BLOOD, 1999

    TCR vaccines against T cell lymphoma

    JOURL OF IMMUNOLOGY, 1999

    TCR vaccines for active immunotherapy of T cell maligncies

    JOURL OF IMMUNOLOGY, 1997

    Idiotype vaccines for non

    BLOOD, 1997

    IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's

    JOURL OF CLINICAL ONCOLOGY, 1997

    IDEC-C2B8 (Rituximab) anti-CD20 monoclol antibody therapy in patients with relapsed low-grade

    BLOOD, 1997

    Ratiole for adjuvant idiotypic vaccition after high-dose therapy for multiple myeloma.

    Biology of blood and marrow transplantation, 1997

    A nine-amino acid peptide from IL-1 beta augments antitumor immune responses induced by protein

    JOURL OF IMMUNOLOGY, 1996

    D immunization induces protective immunity against B-cell lymphoma

    TURE MEDICINE, 1996

    Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccition for B-cell

    BLOOD, 1996

    Surgical resection of large incompletely treated intracranial arteriovenous mal

    JOURL OF NEUROSURGERY, 1996

    Yttrium-90-labeled anti-CD20 monoclol antibody therapy of recurrent B-cell lymphoma

    CLINICAL CANCE

    Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity

    CLINICAL CANCER RESEARCH, 2013

    Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades

    Blood, 2013

    Hierarchy in somatic mutations arising during genomic evolution

    Blood, 2013

    High PD-1 expression

    Blood, 2013

    Self-antigen recognition by follicular lymphoma B-cell receptors

    BLOOD, 2012

    A vaccine directed to B cells

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2012

    CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T

    AMERICAN JOURNAL OF PATHOLOGY, 2012

    Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory

    ONCOIMMUNOLOGY, 2012

    Combination strategies to enhance antitumor ADCC

    IMMUNOTHERAPY, 2012

    Adoptive Cell Therapy for Lymphoma with CD4 T Cells Depleted of CD137-Expressing Regulatory T Cells

    CANCER RESEARCH, 2012

    Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2012

    Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy

    TRENDS IN IMMUNOLOGY, 2011

    Prediction of survival in diffuse large B

    BLOOD, 2011

    Prolonged disease-free survival

    AMERICAN JOURNAL OF HEMATOLOGY, 2011

    Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results

    JOURNAL OF CLINICAL ONCOLOGY, 2011

    The Efficacy of HGAL and LMO2 in the Separation of Lymphom

    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2011

    Immunomodulating antibodies and drugs for the treatment of hematological malignancies

    CANCER AND METASTASIS REVIEWS, 2011

    CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

    BLOOD, 2011

    A CpG-loaded tumor cell vaccine induces antitumor CD4

    Goldstein, M. J., Varghese, B., Brody, J. D., Rajapaksa, R., Kohrt, H., 2011

    Escherichia coli-based production of a tumor idiotype antibody fragment

    PROTEIN EXPRESSION AND PURIFICATION, 2011

    In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

    JOURNAL OF CLINICAL ONCOLOGY, 2010

    Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis

    CELL, 2010

    Immunoarchitectural Patterns in Follicular Lymphoma

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2010

    B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2010

    C-C Chemokine Receptor 1 Expression in Human Hematolymphoid Neoplasia

    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010

    CD81 protein is expressed at high levels in normal germinal center B cells

    HUMAN PATHOLOGY, 2010

    Cell-free production of Gaussia princeps luciferase

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009

    Generation of CD8(+) T cell-mediated immunity against idiotype-negative lymphoma escapees

    BLOOD, 2009

    Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by T-reg depletion

    BLOOD, 2009

    Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant

    IMMUNOTHERAPY, 2009

    Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma

    NEW ENGLAND JOURNAL OF MEDICINE, 2009

    Anti-idiotype antibody response after vaccination correlates with better overall survival in

    BLOOD, 2009

    Vaccines for lymphomas: Idiotype vaccines and beyond

    BLOOD REVIEWS, 2009

    T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need

    BLOOD, 2009

    The Transcription Factor LMO2 Is a Robust Marker of Vascular Endothelium and Vascular Neoplasms

    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009

    Immunotransplantation preferentially expands T-effector cells over T

    BLOOD, 2009

    Idiotype vaccination for lymphoma: moving towards optimisation

    LEUKEMIA & LYMPHOMA, 2009

    Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not

    LEUKEMIA & LYMPHOMA, 2009

    Follicular lymphoma B cells induce the conversion of conventional CD4

    INTERNATIONAL JOURNAL OF CANCER, 2009

    Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or

    LEUKEMIA & LYMPHOMA, 2009

    Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for

    LEUKEMIA & LYMPHOMA, 2009

    Neither CD68+Nor CD163+Macrophages Are Associated with Decreased Survival in Follicular Lymphoma

    Gratzinger, D., Ai, W., Tibshirani, R., Levy, R., Natkunam, Y., 2008

    Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with

    BLOOD, 2008

    LMO2 protein expression predicts survival in patients with diffuse large B

    JOURNAL OF CLINICAL ONCOLOGY, 2008

    Minor BCL2 breakpoints in follicular lymphoma

    JOURNAL OF MOLECULAR DIAGNOSTICS, 2007

    Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the

    JOURNAL OF IMMUNOLOGY, 2007

    Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox

    CANCER RESEARCH, 2007

    Cell-free production of scFv fusion proteins

    BLOOD, 2007

    The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas

    BLOOD, 2007

    Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms

    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007

    Humoral immune response

    BLOOD, 2007

    Expression of the human germinal center-associated lymphoma

    BLOOD, 2007

    Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma. B cells from

    BLOOD, 2006

    Kinetics of B cell receptor signaling

    JOURNAL OF IMMUNOLOGY, 2006

    Production of myeloid dendritic cells

    CYTOTHERAPY, 2006

    Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells

    CANCER RESEARCH, 2005

    Expression of the human germinal center-associated lymphoma (HGAL) protein

    BLOOD, 2005

    Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system

    BIOTECHNOLOGY AND BIOENGINEERING, 2005

    The radioisotope contributes significantly to the activity of radioimmunotherapy

    CLINICAL CANCER RESEARCH, 2004

    Clinical outcome of lymphoma patients after idiotype vaccination

    JOURNAL OF CLINICAL ONCOLOGY, 2004

    Expression of active murine granulocyte-macrophage colony

    BIOTECHNOLOGY PROGRESS, 2004

    AID is expressed in germinal center B-cell-like

    LEUKEMIA, 2004

    Vaccines in lymphoma.

    Clinical advances in hematology & oncology : H&O, 2004

    Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

    NEW ENGLAND JOURNAL OF MEDICINE, 2004

    Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas

    BRITISH JOURNAL OF HAEMATOLOGY, 2004

    TCR vaccines against a murine T cell lymphoma

    JOURNAL OF IMMUNOLOGY, 2004

    Two immunoglobulin G fragment C receptor polymorphisms independently predict response

    JOURNAL OF CLINICAL ONCOLOGY, 2003

    Multiple BCL6 translocation partners in individual cases of gastric lymphoma - Response

    BLOOD, 2003

    BCL6 gene translocation in follicular lymphoma

    BLOOD, 2003

    Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma

    LEUKEMIA & LYMPHOMA, 2003

    The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged

    LEUKEMIA, 2003

    Higher grade transformation of follicular lymphoma

    SEMINARS IN CANCER BIOLOGY, 2003

    Diffuse large B-cell lymphoma: Insights gained from gene expression profiling

    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2003

    Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory

    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003

    Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies

    LEUKEMIA, 2003

    Variation in gene expression patterns in follicular lymphoma and the response to rituximab

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2003

    HGAL is a novel interleukin-4

    BLOOD, 2003

    Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma

    CANCER RESEARCH, 2002

    BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma

    LEUKEMIA, 2002

    Transformation of follicular lymphoma to diffuse large-cell lymphoma

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2002

    In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma

    CANCER RESEARCH, 2002

    Mutation of the ATM gene is not involved

    LEUKEMIA & LYMPHOMA, 2002

    Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma

    BLOOD, 2002

    Rapid establishment of dendritic cell chimerism

    BLOOD, 2002

    BLyS* and BLyS receptor expression in non-Hodgkin's lymphoma

    EXPERIMENTAL HEMATOLOGY, 2002

    Apoptosis stimulating protein of p53

    LEUKEMIA & LYMPHOMA, 2002

    A polymorphism in the BCL-6 gene is associated with follicle center lymphoma

    LEUKEMIA & LYMPHOMA, 2001

    Re: Akasaka, H., et al., Molecular anatomy of BCL6 translocations revealed by long

    Cancer research, 2001

    Expression of complement inhibitors CD46, CD55

    BLOOD, 2001

    Expression of a single gene, BCL-6

    BLOOD, 2001

    Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B

    BLOOD, 2001

    T cell antigen receptor vaccines for active therapy of T cell malignancies

    Reddy, S. A., Okada, C., Wong, C., Bahler, D., Levy, R., 2001

    Idiotype vaccination following ABMT can stimulate specific anti

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001

    The inference of antigen selection on Ig genes

    JOURNAL OF IMMUNOLOGY, 2000

    A perspective on monoclonal antibody therapy: Where we have been and where we are going

    Levy, R., 2000

    The history of the development of vaccines for the treatment of lymphoma.

    Clinical lymphoma, 2000

    Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma

    JOURNAL OF CLINICAL ONCOLOGY, 2000

    Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2000

    Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the

    BLOOD, 2000

    Combination immunotherapy of relapsed or refractory low-grade or follicular non

    CLINICAL CANCER RESEARCH, 2000

    Recombinant adenovirus vaccine encoding a chimeric T

    CANCER RESEARCH, 2000

    Linkage of foreign carrier protein to a self

    JOURNAL OF IMMUNOLOGY, 2000

    Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas

    BLOOD, 2000

    Mutation analysis of the 5 ' noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma

    BLOOD, 2000

    Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

    NATURE, 2000

    Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000

    Cytokine fusion constructs as DNA vaccines against tumors.

    Methods in molecular medicine, 2000

    'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns.

    Genome biology, 2000

    Karnofsky Lecture: Immunotherapy of lymphoma

    JOURNAL OF CLINICAL ONCOLOGY, 1999

    1999 keystone symposium on B lymphocyte biology and disease: B cell malignancy II session.

    Levy, R.

    Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma

    JOURNAL OF CLINICAL ONCOLOGY, 1999

    DNA vaccination against the idiotype of a murine B cell lymphoma: Mechanism of tumor protection

    JOURNAL OF IMMUNOLOGY, 1999

    Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell

    BLOOD, 1999

    TCR vaccines against T cell lymphoma

    JOURNAL OF IMMUNOLOGY, 1999

    Dendritic cell vaccines for cancer immunotherapy

    ANNUAL REVIEW OF MEDICINE, 1999

    Anti-idiotype antibodies can induce long

    BLOOD, 1998

    Stereotactic radiosurgery of angiographically occult vascular malformations: 14-year experience

    NEUROSURGERY, 1998

    Pathological changes in surgically resected angiographically occult v

    NEUROSURGERY, 1998

    Identification of peptide lig

    Methods in molecular biology (Clifton, N.J.), 1998

    TCR vaccines for active immunotherapy of T cell malignancies

    JOURNAL OF IMMUNOLOGY, 1997

    Idiotype vaccines for non

    BLOOD, 1997

    IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's

    JOURNAL OF CLINICAL ONCOLOGY, 1997

    IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade

    BLOOD, 1997

    Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.

    Biology of blood and marrow transplantation, 1997

    Tumor-specific idiotype vaccines in the treatment of patients with B

    BLOOD, 1997

    A nine-amino acid peptide from IL-1 beta augments antitumor immune responses induced by protein

    JOURNAL OF IMMUNOLOGY, 1996

    DNA immunization induces protective immunity against B-cell lymphoma

    NATURE MEDICINE, 1996

    Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell

    BLOOD, 1996

    Surgical resection of large incompletely treated intracranial arteriovenous mal

    JOURNAL OF NEUROSURGERY, 1996

    Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma

    CLINICAL CANCE

    What is Dr. Levy's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.

    Dr. Levy's National Provider Identifier (NPI) number is 1851427025.

    What common questions do patients ask about Dr. Levy?

    Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Levy

    What is Dr. Ronald Levy's specialty?

    Dr. Levy is a Medical Oncologist near Stanford, CA. An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options. Contact Dr. Levy to book an appointment today.

    Is this Dr. Ronald Levy affiliated with a ranked Castle Connolly Top Hospital?

    Yes, Dr. Levy is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals

    Where can I learn more about Medical Oncologist?

    Explore Medical Oncologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.

    Is Ronald Levy accepting new patients in Stanford, CA?

    Yes, Dr. Ronald Levy is accepting new patients at this time.

    Does Dr. Ronald Levy offer online booking?

    Please contact Dr. Levy's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.

    How can I make an appointment with Ronald Levy?

    Please contact Dr. Levy's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.

    Which board certifications does Dr. Ronald Levy have?

    Dr. Ronald Levy is certified by the American Board of Internal Medicine.

    Other Medical Oncologist Near Stanford, CA

    NM

    Medical Oncologist

    acceptingPatients-iconAccepting patients
    Stanford, CA
    JD

    Medical Oncologist

    acceptingPatients-iconAccepting patients
    Stanford, CA
    AK

    Medical Oncologist

    acceptingPatients-iconAccepting patients
    Stanford, CA
    See All Specialists

    Doctors by Category

    Specialists